The Au-Gd3+-PSMA NPs show good tumor-targeting specificity, high MR contrast, significant in vivo radiation dose amplification, and renal clearance ability, which exhibit great potential in the clinical MR-guided radiotherapy of PSMA-positive solid tumors ((as shown in Figure 4b). This evidence concerns the gene FOLH1 and neoplasm.